Form 4: Protagenic Therapeutics Executive Chairman Acquires 250,000 Stock Options

Garo H. Armen, Executive Chairman of Protagenic Therapeutics, acquired 250,000 stock options on March 25, 2024, according to a Form 4 filing.

Summary

• Garo H. Armen, the Executive Chairman of Protagenic Therapeutics, Inc. (PTIX), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 25, 2024, where Armen acquired 250,000 options to purchase PTIX common stock.
• The exercise price of these options is $1.74.
• The options vest monthly over 36 months starting from the grant date and fully vest upon a change of control.
• The options expire on March 25, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of options by the Executive Chairman could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options by the Executive Chairman could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by the Executive Chairman as a positive sign, aligning management's interests with theirs.

Key Dates

Keywords

Form 4, Protagenic Therapeutics, Stock Options, Beneficial Ownership, Garo H. Armen, PTIX, Executive Chairman